1473 - A 50 gene signature assay for predicting breast cancer recurrence

Page last updated: 21 March 2017

Application Detail

Status

Open

Description of Medical Service

The assay provides a 50 gene profile that is used to assess the prognosis and predict response to treatment of breast cancer patients. The Risk of Recurrence (ROR) score is based on the identification of the four intrinsic breast cancer subtypes, Luminal A, Luminal B, HER2-enriched, and Basal-like. The unique genetic profile is produced using a diagnostic kit which quantifies mRNA expression and can be performed in local laboratories provided they have the NanoString nCounter® Dx technology (Prosigna enabled).

Description of Medical Condition

Prosigna® is a 50-gene test that is designed to identify intrinsic breast cancer subtypes and to generate a Risk of Recurrence (ROR) score. This is then used to tailor the most appropriate therapy for that type of primary breast cancer. It will be used for women with HER2 –ve, ER and/or PR +ve breast cancer who do not have clear cut treatment choices.

Reason for Application

New Application

Medical Service Type

therapeutic

Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 428 KB)
Application Form (Word 175 KB)

Consultation Survey

Consultation Survey (PDF 97 KB)
Consultation Survey (Word 508 KB)

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

12 April 2017

ESC

-

MSAC

-